2. Academic Validation
  3. Immune Profiling of Medullary Thyroid Cancer-An Opportunity for Immunotherapy

Immune Profiling of Medullary Thyroid Cancer-An Opportunity for Immunotherapy

  • Genes (Basel). 2021 Sep 28;12(10):1534. doi: 10.3390/genes12101534.
Kinga Hińcza-Nowak 1 2,  Artur Kowalik 1 3,  Agnieszka Walczyk 2 4,  Iwona Pałyga 2 4,  Danuta Gąsior-Perczak 2 4,  Agnieszka Płusa 5,  Janusz Kopczyński 5,  Magdalena Chrapek 6,  Stanisław Góźdź 4 7,  Aldona Kowalska 2 4
Affiliations

Affiliations

  • 1 Department of Molecular Diagnostics, Holycross Cancer Centre, 25-734 Kielce, Poland.
  • 2 Endocrinology Clinic, Holycross Cancer Centre, 25-734 Kielce, Poland.
  • 3 Division of Medical Biology, Institute of Biology, Jan Kochanowski University, 25-406 Kielce, Poland.
  • 4 Collegium Medicum, Jan Kochanowski University, 25-319 Kielce, Poland.
  • 5 Surgical Pathology, Holycross Cancer Centre, 25-734 Kielce, Poland.
  • 6 Faculty of Natural Sciences, Jan Kochanowski University, 25-406 Kielce, Poland.
  • 7 Clinical Oncology, Holycross Cancer Centre, 25-734 Kielce, Poland.
PMID: 34680929 DOI: 10.3390/genes12101534
Abstract

Medullary thyroid Cancer (MTC) is a rare malignancy that arises from calcitonin-producing C-cells. Curative treatment for patients with metastatic MTC is challenging. Identifying the mechanisms by which Cancer cells inhibit the activity of immune cells provides an opportunity to develop new therapies that restore Anticancer activity. Little is known about the immunological phenomena underlying MTC. Here, we examined the expression profile of 395 genes associated with MTC. The study included 51 patients diagnosed with MTC at a single center. Bioinformatical analysis revealed that CD276 expression in MTC cells was at least three-fold higher than that in normal tissue. The expression of CD276 showed a weak but statistically significant positive correlation with tumor diameter, but we did not find a significant association between CD276 expression and other histopathological clinical factors, or the response to initial therapy. A search of published data identified the monoclonal antibody (inhibitor) enoblituzumab as a potential drug for patients diagnosed with MTC overexpressing CD276.

Keywords

CD276; immunotherapy; medullary thyroid cancer.

Figures
Products